New medical advancements are making surgery less invasive for those with Aortic Valve Disease. When the aortic heart valve ...

JenaValve today announced the successful first cases and official U.S. commercial launch of its Trilogy heart valve system.

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the successful first cases and official U.S. commercial launch of the ...

Early valve replacement surgery for very severe asymptomatic aortic stenosis was tied to lower long-term mortality risk ...

This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

PRO-TAVI trial shows net clinical benefit compared with PCI before valve replacement ...

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable ...

Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.

At 10 years, early surgery continues to have a mortality benefit when compared with conservative care for asymptomatic aortic ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.